Randomized comparison of health-related quality of life in women with ectopic pregnancy or pregnancy of unknown location treated with systemic methotrexate or expectant management

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)

Abstract

To study the impact on health-related quality of life (HRQoL) of treatment with systemic methotrexate (MTX) or expectant management in women with ectopic pregnancy or pregnancy of unknown location (PUL) with low and plateauing serum hCG concentrations. HRQoL was assessed alongside a randomized clinical trial (RCT) with the use of standard self-administered psychometric measure questionnaires. All women who participated in the multicenter RCT comparing treatment with systemic MTX to expectant management in women with ectopic pregnancy or persisting PUL were eligible for the HRQoL measurements. HRQoL measures of three standardized questionnaires (SF-36, RSCL, HADS). Data were available for 64 of 73 women (78%) randomized in the RCT. We found no difference in HRQoL between the two treatment groups. The need for additional treatment, i.e. additional MTX injections or surgical intervention, had no impact on HRQoL. Women treated with MTX or expectant management for an ectopic pregnancy or persisting PUL have comparable quality of life
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalEuropean journal of obstetrics, gynecology, and reproductive biology
Volume192
DOIs
Publication statusPublished - Sept 2015

Keywords

  • Abortifacient Agents, Nonsteroidal/therapeutic use
  • Abortion, Therapeutic
  • Adult
  • Chorionic Gonadotropin/blood
  • Female
  • Health Status
  • Humans
  • Methotrexate/therapeutic use
  • Pregnancy
  • Pregnancy, Ectopic/drug therapy
  • Quality of Life
  • Surveys and Questionnaires
  • Watchful Waiting

Cite this